期刊文献+

强化宣传教育对血液透析患者高磷血症的疗效观察 被引量:6

下载PDF
导出
摘要 钙磷代谢异常是维持性血液透析患者的常见并发症。高磷血症、钙磷代谢异常及继发性甲状旁腺功能亢进与维持性血液透析患者肾性骨病、心血管钙化及心血管死亡相关[1~4]。控制患者高磷血症,将血磷维持于达标水平,可以防止肾性骨营养不良和转移性钙化等并发症,能改善患者的长期预后[5]。碳酸钙是我国目前最常用的磷结合剂。我们设想通过加强宣传教育,提高患者服用钙剂的依从性,从而更有效地降低高磷血症患者的血磷水平。
出处 《中国中西医结合肾病杂志》 2014年第5期437-438,共2页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 "十二五"国家科技支撑计划资助项目(No.2011BA110B00) 广东省大学生创新实验项目(No.1055812326) 中山大学医科2012年第一批学生业余科研暨科研助理计划项目立项项目(No.78)
  • 相关文献

参考文献10

二级参考文献52

  • 1马璐璐,刘毅,王刚.健康宣教对维持性透析患者钙磷的影响[J].中国实用护理杂志(下旬版),2005,21(2):58-59. 被引量:23
  • 2梁馨苓,史伟,章斌,刘双信,林秋雄,黄美萍,王文健,叶智明,何朝生.终末期肾病患者心血管事件与血清胎球蛋白A及冠脉钙化的关系[J].中华肾脏病杂志,2006,22(6):336-340. 被引量:25
  • 3王海燕.循证医学在我国肾脏病学科发展中的应用现状与展望[J].中华肾脏病杂志,2007,23(3):137-139. 被引量:11
  • 4The International Quotidian Dialysis Registry:annunal report 2005.Hemodial Int,2005,9 (3):203-209.
  • 5Nieto FJ,Iribarren C,Gross MD,et al.Uric acid and serum an-tioxidant capacity:a reaction to atherosclerosis? Atherosclero-sis,2000,148(2):131-139.
  • 6Baker JF,Krishnan E,Chen L,et al.Serum uric acid and cardio-vascular disease:recent developments,and where do they leave us? Am J Med,2005,118(8):816-826.
  • 7Kang DH,Park SK,Lee IK,et al.Uric acid-induced C-reac-tive protein expression; implication on cell proliferation and ni-tric oxide production of human vascular ceils.J Am Soc Nephrol,2005,16(12):3553-3562.
  • 8Madsen T,Skou HA,Hansen VE,et al.C-reactive protein,di-etary n-3 fatty acids and the coronary disease.Am J Cardiol,2001,88(10):1139-1142.
  • 9Rostand SG,Rutsky EA.Cardiac Disease in Dialysis Patients.In:Nissenson AR.Clinical Dialysis.2nd ed.Norwalk,Appleton and Hange,1990.409-446.
  • 10Block GA,Klassen PS,Lazarus JM,et al.Mineral metabolism,mortality,and morbidity in maintenance hymodialysis.J Am Soc Nephrol,2004,15 (8):2208-2218.

共引文献54

同被引文献66

  • 1史均宝,朱宁,田信奎,郑丹侠,王悦.维持性血液透析患者营养状态对预后影响的临床研究[J].中国血液净化,2012,11(3):124-127. 被引量:31
  • 2杨筱敏,叶白如,金领微,葛红.维持性血液透析患者并发严重高钙血症的观察与护理21例[J].中国实用护理杂志(下旬版),2006,22(5):13-14. 被引量:1
  • 3徐耀文,汪关煜,钱莹,朱萍,吴霞珺,杨泽彬,陈楠.低钙透析联合碳酸钙治疗血透患者高磷血症[J].中国实用内科杂志:临床前沿版,2006,26(6):907-910. 被引量:10
  • 4潘明明,苗华.高磷血症治疗新进展[J].国际移植与血液净化杂志,2006,4(6):12-14. 被引量:9
  • 5National Kidney Foundation. K/DOQI Clinical Practice Guide- lines for Bone Metabolism and Disease in Chronic Kidney Dis- ease. American Journal of Kidney Diseases ,2003,42( suppl 3 ) : 1 - 202.
  • 6刘志红,王莉,陈江华,等.慢性肾脏病矿物质和骨异常诊治指导.中华肾脏病杂志,2014,30(增刊):14-34.
  • 7Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phos- phate, and the risk of mortality in a European haemodialysis pop-ulation. Nephrology Dialysis Transplantation, 2011,26 ( 6 ) : 1948 - 1955.
  • 8Palmer Suetonia C, Andrew H, Petra M, et al. Serum Le-els of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardio-ascular Disease in Indi-iduals With Chronic Kidney Disease. Journal of the American Medical Association, 2011,305(11 ) :1119 - 1127.
  • 9Nigel D,Toussaint T, Pedagogos E, et al. Impro-ing CKD - MBD management in haemodialysis patients:barrier analysis for imple- menting better practice. Nephrology Dialysis Transplantation, 2011,26(4) :1319 - 1326.
  • 10Brian Copley J,Pratt R, Martin P, et al. 68 Lanthanum Carbonate (LC) -s Se-elamer for Treating Hyperphosphatemia in CKD. A- merican Journal of Kidney Diseases,2011,57 (4) : B33.

引证文献6

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部